CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Listed Company

CELZCIK 0001187953NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)NevadaFY ends Dec 31

Period

FY 2025

Revenue

$6.0K

Net Income

$-6.00M

Total Assets

—

Equity

—

Shares Out

3.70M

Op. Cash Flow

$-5.86M

Business

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. is a commercial-stage biotechnology company focused on identifying and translating novel biological therapeutics in immunotherapy, endocrinology, urology, neurology, and orthopedics. Its main products and platforms include ImmCelz™ (CELZ-100), AlloStem™ (CELZ-201-DDT), StemSpine®, CaverStem®, FemCelz®, OvaStem™, and iPScelz™ for both autologous and allogenic cell therapies and related cell-free products. Key business units include subsidiaries Creative Medical Technologies, Inc., ImmCelz, Inc., StemSpine, Inc., and AlloCelz LLC supporting platform development and clinical programs. The company conducts FDA‑regulated clinical trials, physician‑administered outpatient procedures, and research collaborations primarily in the United States with third‑party partners and CROs.

Summary from filing dated 2025-03-14

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenues	6,000	11,000	9,000	88,600	87,754
Cost of revenues	2,194	4,400	3,600	28,491	47,949
Gross profit	3,806	6,600	5,400	60,109	39,805
Research and development	2	2	2	6	109,180
Selling, general and administrative	4	3	4	4	3
Amortization of patent costs	123,327	110,452	94,584	92,084	92,084
TOTAL EXPENSES	6	6	6	10	3
Operating loss	−6	−6	−6	−10	−3
Interest income	147,806	250,380	333,558	100,328	—
Total other income (expense)	147,806	250,380	333,558	100,328	22
LOSS BEFORE PROVISION FOR INCOME TAXES	−6	−5	−5	−10	19
Provision for income taxes	0	0	—	—	—
NET LOSS	−6	−5	—	—	—
Net income attributable to non-controlling interest	0	0	—	—	—
NET LOSS ATTRIBUTABLE TO CMTH	−6	−5	−5	−10	19
NET LOSS PER SHARE - BASIC AND DILUTED	−2.52	−3.71	−3.76	−0.93	5.61
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	2	1	1	11	3

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash	7	6	3	8	—
Inventory	0	2,194	6,594	10,194	10,866
Note receivable, net of premium	52,084	0	—	—	—
Prepaids and other current assets	138,804	192,707	277,246	338,120	0
Total Current Assets	7	6	10	19	11
Other assets	3,281	3,281	3,281	3,281	3,281
Licenses, net of amortization	407,230	530,559	441,011	435,595	527,679
TOTAL ASSETS	8	7	11	19	11
Accounts payable	270,686	273,530	317,280	3	761,862
Accrued expenses	0	39,920	39,920	39,920	24,385
Advances from related party	14,194	14,194	14,194	14,194	—
Total Current Liabilities	284,880	327,644	371,394	3	1
TOTAL LIABILITIES	284,880	327,644	371,394	3	1
Preferred stock, $0.001 par value, 10,000,000 shares authorized at December 31, 2025 and 2024	0	0	0	—	0
Common stock, $0.001 par value, 25,000,000 shares authorized; 3,701,668 and 1,748,428 issued and 3,696,668 and 1,748,428 outstanding at December 31, 2025 and 2024, respectively	3,144	1,749	1,431	1,407	6,339
Additional paid-in capital	78	71	70	70	54
Accumulated deficit	−71	−65	−59	−54	−44
Treasury stock, at cost, 5,000 and 0 shares as of December 31, 2025 and 2024, respectively	−10,000	0	−270,952	—	—
TOTAL STOCKHOLDERS' EQUITY	8	6	10	16	10
Non-controlling interest	10,000	0	—	—	—
TOTAL EQUITY ATTRIBUTABLE TO CMTH	8	6	10	—	—
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	8	7	11	19	11

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	3,485	36,648	36,648	68,746	595,380
Amortization of note receivable premium	−1,584	0	—	—	—
Inventory	2,194	4,400	3,600	672	−10,866
Prepaids and other current assets	53,903	84,539	108,202	−338,120	0
Accounts payable	−2,842	−43,850	−3	3	410,963
Accrued expenses	−39,920	0	0	15,535	20,635
Advances from related party	0	0	—	—	—
Net cash used in operating activities	−6	−5	−8	−8	−2
Issuance of note receivable	−50,500	0	—	—	—
Redemptions of investments	0	7	—	—	—
Payment of patent purchase obligation - related party	0	−200,000	−100,000	—	—
Net cash provided by (used in) investing activities	−50,500	6	3	−10	0
Contribution from minority member	10,000	0	—	—	—
Purchase of treasury stock	−10,000	−174,964	−270,952	0	—
Proceeds from sale of common stock and warrants, net of issuance costs	7	2	0	15	15
Proceeds from sale of Series B preferred stock	0	100	0	—	—
Net cash provided by financing activities	7	1	−270,952	15	13
NET CHANGE IN CASH	1	2	—	—	—
Cash payments for interest	0	0	0	0	9,186
Cash payments for income taxes	0	0	0	0	0
Cancellation of Series B preferred stock within accounts payable	0	100	0	—	—
Cancellation of treasury stock	0	445,916	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro